Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.74 |
| ▸ | MEN1 | O00255 | 10/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.74 |
| ▸ | POLB | P06746 | 9/20 | 0.74 |
| ▸ | PKM | P14618 | 5/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | APEX1 | P27695 | 4/20 | 0.72 |
| ▸ | PTPN22 | Q9Y2R2 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 2/20 | 0.72 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.64 |
| ▸ | ITGAM | P11215 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 7/20 | 0.63 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094536 | 1.00 | KMT2A (0.74) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL29441247 | 1.00 | KMT2A (0.74) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL29651506 | 0.94 | MEN1 (0.74) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL14426584 | 0.94 | MEN1 (0.74) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL28185420 | 0.94 | MEN1 (0.74) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL23662285 | 0.89 | KMT2A (0.69) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL14507111 | 0.86 | MEN1 (0.69) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL14426567 | 0.85 | KMT2A (1.00) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL29701306 | 0.85 | KMT2A (1.00) | KMT2AMEN1TDP1POLBPKM | |
| SCHEMBL14507110 | 0.85 | KMT2A (1.00) | KMT2AMEN1TDP1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635508-A2 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | Yeda Research and Development Co. Ltd (IL) | 2025-10-22 | — | — | EP | disclosed |
| EP-3116542-B1 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | YEDA RES & DEV (IL) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182566-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| US-11884728-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-30 | — | — | US | disclosed |
| EP-4269439-A2 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | Yeda Research and Development Co. Ltd (IL) | 2023-11-01 | — | — | EP | disclosed |
| CN-116492457-A | Lowering systemic regulatory T cell levels or activity for treatment of diseases and injuries of the central nervous system | 耶达研究与开发有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-108348607-B | Lowering systemic regulatory T cell levels or activity for treatment of diseases and injuries of the central nervous system | 耶达研究与开发有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230183350-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-11643464-B2 | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder | Yeda Research and Develpment & Co. Ltd (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11492405-B2 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2022-11-08 | — | — | US | disclosed |
| US-20170029508-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2017-02-02 | — | — | US | disclosed |
| US-9534052-B2 | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2017-01-03 | — | — | US | disclosed |
| US-9512225-B2 | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-12-06 | — | — | US | disclosed |
| US-9512227-B2 | Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-12-06 | — | — | US | disclosed |
| US-20160319021-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-11-03 | — | — | US | disclosed |
| US-20160311905-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-10-27 | — | — | US | disclosed |
| US-20160297880-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-10-13 | — | — | US | disclosed |
| US-9394365-B1 | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2016-07-19 | — | — | US | disclosed |
| US-20160008463-A1 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-01-14 | — | — | US | disclosed |
| US-20160000909-A1 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | YEDA RESEARCH AND DEVELOPMENT CO. LTD (IL) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183350-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | CD4, NFATC1, TSLP | KMT2A 2245/4885MEN1 3171/4885TDP1 1260/4885 |
| US-20240182566-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | CD4, PMP22, GMFG | KMT2A 2565/4885MEN1 3719/4885TDP1 1719/4885 |
| US-20170029508-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | CD4, NFATC1, TSLP | KMT2A 2245/4885MEN1 3171/4885TDP1 1260/4885 |
| US-20160311905-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | CD4, TSLP, IL2 | KMT2A 2542/4885MEN1 2789/4885TDP1 977/4885 |
| US-11643464-B2 | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder | ALDH1A2, RBP4, RBP1 | KMT2A 3455/4885MEN1 4216/4885TDP1 751/4885 |
| US-11492405-B2 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS | CD4, NFATC1, TSLP | KMT2A 2245/4885MEN1 3171/4885TDP1 1260/4885 |
| US-20160297880-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | CD4, TSLP, IL2 | KMT2A 2542/4885MEN1 2789/4885TDP1 977/4885 |
| US-20160319021-A1 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease | CD4, TSLP, IL2 | KMT2A 2542/4885MEN1 2789/4885TDP1 977/4885 |
| US-20160000909-A1 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | CD4, PMP22, GMFG | KMT2A 2675/4885MEN1 3664/4885TDP1 1648/4885 |
| US-11884728-B2 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | IL2, PMP22, TSLP | KMT2A 2625/4885MEN1 4641/4885TDP1 755/4885 |
| US-20160008463-A1 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS | CD4, PMP22, GMFG | KMT2A 2565/4885MEN1 3719/4885TDP1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.